2022
Association between household composition and severe COVID-19 outcomes in older people by ethnicity: an observational cohort study using the OpenSAFELY platform
Wing K, Grint DJ, Mathur R, Gibbs HP, Hickman G, Nightingale E, Schultze A, Forbes H, Nafilyan V, Bhaskaran K, Williamson E, House T, Pellis L, Herrett E, Gautam N, Curtis HJ, Rentsch CT, Wong AYS, MacKenna B, Mehrkar A, Bacon S, Douglas IJ, Evans SJW, Tomlinson L, Goldacre B, Eggo RM. Association between household composition and severe COVID-19 outcomes in older people by ethnicity: an observational cohort study using the OpenSAFELY platform. International Journal Of Epidemiology 2022, 51: 1745-1760. PMID: 35962974, PMCID: PMC9384728, DOI: 10.1093/ije/dyac158.Peer-Reviewed Original ResearchRisk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
MacKenna B, Kennedy NA, Mehrkar A, Rowan A, Galloway J, Matthewman J, Mansfield KE, Bechman K, Yates M, Brown J, Schultze A, Norton S, Walker AJ, Morton CE, Harrison D, Bhaskaran K, Rentsch CT, Williamson E, Croker R, Bacon S, Hickman G, Ward T, Davy S, Green A, Fisher L, Hulme W, Bates C, Curtis HJ, Tazare J, Eggo RM, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson LA, Mathur R, Wong AYS, Forbes H, Parry J, Hester F, Harper S, Douglas IJ, Smeeth L, Lees CW, Evans SJW, Goldacre B, Smith CH, Langan SM. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. The Lancet Rheumatology 2022, 4: e490-e506. PMID: 35698725, PMCID: PMC9179144, DOI: 10.1016/s2665-9913(22)00098-4.Peer-Reviewed Original ResearchImmune-mediated inflammatory diseasesCOVID-19-related deathsSevere COVID-19 outcomesImmune-modifying therapiesCritical care admissionInflammatory diseasesCOVID-19 outcomesImmune-modifying drugsHospital admissionGeneral populationCare admissionHazard ratioStandard systemic therapyStandard systemic treatmentSevere COVID-19Primary care recordsPrimary care dataNon-white ethnic groupsCohort studySystemic therapySystemic treatmentCox regressionPrescription dataCare recordsWhite ethnic groupAssociation between oral anticoagulants and COVID-19 related outcomes: a population-based cohort study
Wong AY, Tomlinson L, Brown JP, Elson W, Walker AJ, Schultze A, Morton CE, Evans D, Inglesby P, MacKenna B, Bhaskaran K, Rentsch CT, Powell E, Williamson E, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Cockburn J, McDonald HI, Mathur R, Wing K, Forbes H, Eggo RM, Evans SJ, Smeeth L, Goldacre B, Douglas IJ, . Association between oral anticoagulants and COVID-19 related outcomes: a population-based cohort study. British Journal Of General Practice 2022, 72: bjgp.2021.0689. PMID: 35440465, PMCID: PMC9037187, DOI: 10.3399/bjgp.2021.0689.Peer-Reviewed Original ResearchConceptsCOVID-19 outcomesPopulation-based cohort studySevere COVID-19 outcomesSARS-CoV-2Oral anticoagulantsLower riskVASc scoreCohort studyHazard ratioAtrial fibrillationCOVID-19 related outcomesCOVID-19-related deathsPrescribed oral anticoagulantsPrimary care dataBaseline stroke riskOAC useCurrent useStroke riskHospital admissionThrombotic eventsCox regressionOAC usersReduced infection riskGeneral practiceDeath recordsOverall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform
Bhaskaran K, Rentsch CT, Hickman G, Hulme WJ, Schultze A, Curtis HJ, Wing K, Warren-Gash C, Tomlinson L, Bates CJ, Mathur R, MacKenna B, Mahalingasivam V, Wong A, Walker AJ, Morton CE, Grint D, Mehrkar A, Eggo RM, Inglesby P, Douglas IJ, McDonald HI, Cockburn J, Williamson EJ, Evans D, Parry J, Hester F, Harper S, Evans SJ, Bacon S, Smeeth L, Goldacre B. Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform. PLOS Medicine 2022, 19: e1003871. PMID: 35077449, PMCID: PMC8789178, DOI: 10.1371/journal.pmed.1003871.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsCOVID-19 hospitalisationGeneral population controlsCOVID-19 groupCOVID-19 survivorsHospital admissionHigh riskInfluenza hospitalisationsCause mortalityCohort studyInfluenza patientsPrimary careGeneral populationInitial infectionAcute coronavirus disease 2019Lower respiratory tract infectionsSevere COVID-19 outcomesLong-term adverse outcomesCOVID-19 hospital admissionsSpecific causesPopulation controlsCause-specific hospitalisationRespiratory tract infectionsCause-specific outcomesPotential risk factors
2021
A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data Report
Rowan A, Bates C, Hulme W, Evans D, Davy S, Kennedy N, Galloway J, Mansfield K, Bechman K, Matthewman J, Yates M, Brown J, Schultze A, Norton S, Walker A, Morton C, Bhaskaran K, Rentsch C, Williamson E, Croker R, Bacon S, Hickman G, Ward T, Green A, Fisher L, Curtis H, Tazare J, Eggo R, Inglesby P, Cockburn J, McDonald H, Mathur R, Wong A, Forbes H, Parry J, Hester F, Harper S, Douglas I, Smeeth L, Tomlinson L, Lees C, Evans S, Smith C, Langan S, Mehkar A, MacKenna B, Goldacre B. A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data Report. Wellcome Open Research 2021, 6: 360. PMID: 35634533, PMCID: PMC9120928, DOI: 10.12688/wellcomeopenres.17360.1.Peer-Reviewed Original ResearchHigh-cost drugsSevere COVID-19 outcomesMonths of drugUnique patient IDCOVID-19 outcomesCOVID-19 pandemicLong-term conditionsNHS DigitalNHS EnglandCertain medicinesPatientsSpecialist medicinePatient IDDrugsDrug namesHospitalAverage numberMedicine dataMedicineDescriptive analysisReportYearsOpenSAFELYPandemicData reports